

# SynovAI

## *Retrosynthesis Realized*



# The SynovAI team delivers leading innovation, technical expertise, and operational experience



**Victor Batista, PhD**  
Co-Founder  
Board Member  
Kirkwood Professor of Chemistry



**Jessica Freeze, PhD**  
Co-Founder  
Board Member  
President & Chief Executive Officer



**Klas Holmlund, MBA, CFA**  
Co-Founder  
Chief Operating Officer



**Corey Jones, PhD**  
Co-Founder  
Chief Scientific Officer



Yale *Energy Sciences Institute*

**JCTC**  
Journal of Chemical Theory and Computation




# Costly tradeoffs from growing molecular complexity magnifies launch risks and increases production costs

## Analgesics (Pain)


### *ibuprofen*

1998, 3 steps



### *atogepant*


2021, 10 steps



## Anti-virals (HIV)



### *zidovudine*

1987, 3 steps



### *lenacapavir*


2022, >20 steps



# SynovAI's generative retrosynthesis platform demonstrates real synthetic improvement across key metrics

Orforglipron – Oral GLP-1 Inhibitor currently in Phase III trials

## Current Synthesis



Planning Time

Synthesis Duration

Purification


Yield

Waste/Greenness

COGS






## SynovAI Synthesis Improvements



# SynovAI's platform outperforms other computational methods with a clear technological competitive edge


**KRAS G12C Inhibitor Intermediate** – Tumorigenic Mutation: *Demonstrated novel synthetic pathway, unseen by current commercial software, within two weeks*

	Competition	SynovAI
<div><b>SynovAI<sup>1</sup></b></div> <div></div>	<div>No Data Querying</div> <div>No Hand -Coded Rules</div> <div>Novel Pathways</div>	<div>—</div> <div>—</div> <div>—</div> <div>✓</div> <div>✓</div> <div>✓</div>
<div><b>Previous Best<sup>2</sup></b></div> <div></div>	<div>Experimentally Validated</div> <div>Efficient Scaling with Pathway Size</div> <div>Prototype Ready for Use</div>	<div>✓</div> <div>—</div> <div>✓</div> <div>✓</div> <div>✓</div> <div>✓</div>

1) <https://doi.org/10.26434/chemrxiv-2024-zscw8>

2) <https://doi.org/10.1021/acs.oprd.3c00363>

# SynovAI's technology is ready for deployment and growth potential is substantial




Platform  
Live



Process  
Validation  
IP generation

Process based platform development enables creation of new IP and potential for multiple strategic partnerships


# SynovAI's chemical retrosynthesis solution can provide exclusive and significant value across many industries globally



Source: ACC 2023 Guide to the Business of Chemistry; assumes aggregate cross-industry Cost-of-Goods-Sold (COGS) and retrosynthesis applicability of 30% and 5%, respectively



# SynovAI's business model delivers immediate partnerships benefits, IP generation capabilities and enduring revenue scalability





# Projected Timeline: SynovAI can deliver multiple valuation inflection points in rapid succession

6 Months

12 Months

18 Months

## Improved Pathway Partnerships

*Fundraising*

*Retrosynthesis Partnership Deals*

## CRO/CDMO: Improved Pathway to Gram Synthesis and CMC Scalability

*Lab Setup*

*CRO/CDMO Partnership Deals*

## Chemical Process Asset Generation

*Identify and validate priority asset targets*

*Process Patents*



Potential valuation and fundraising catalyst

# Come talk to us!



**Victor Batista, PhD**  
Co-Founder  
Board Member  
Kirkwood Professor of Chemistry



**Jessica Freeze, PhD**  
Co-Founder  
Board Member  
President & Chief Executive Officer



**Klas Holmlund, MBA, CFA**  
Co-Founder  
Chief Operating Officer



**Corey Jones, PhD**  
Co-Founder  
Chief Scientific Officer



[info@synovai.net](mailto:info@synovai.net)